Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

BUY
$0.29 - $0.45 $5,694 - $8,836
19,636 Added 4.14%
493,702 $177,000
Q3 2023

May 14, 2024

SELL
$0.34 - $0.69 $6,676 - $13,548
-19,636 Reduced 3.98%
474,066 $161,000
Q3 2023

Nov 14, 2023

BUY
$0.34 - $0.69 $104,836 - $212,755
308,342 Added 186.06%
474,066 $161,000
Q2 2023

May 14, 2024

BUY
$0.52 - $0.91 $25,825 - $45,194
49,664 Added 42.79%
165,724 $87,000
Q2 2023

Aug 14, 2023

BUY
$0.52 - $0.91 $25,825 - $45,194
49,664 Added 42.79%
165,724 $87,000
Q1 2023

May 14, 2024

BUY
$0.7 - $1.41 $23,510 - $47,356
33,586 Added 40.72%
116,060 $87,000
Q1 2023

May 11, 2023

BUY
$0.7 - $1.41 $23,510 - $47,356
33,586 Added 40.72%
116,060 $87,000
Q4 2022

May 14, 2024

SELL
$0.97 - $45.0 $93,212 - $4.32 Million
-96,095 Reduced 53.81%
82,474 $98,000
Q4 2022

Feb 13, 2023

SELL
$0.97 - $45.0 $93,212 - $4.32 Million
-96,095 Reduced 53.81%
82,474 $98,000
Q3 2022

May 14, 2024

SELL
$1.22 - $40.8 $179,425 - $6 Million
-147,070 Reduced 45.16%
178,569 $232,000
Q3 2022

Nov 10, 2022

SELL
$1.22 - $40.8 $179,425 - $6 Million
-147,070 Reduced 45.16%
178,569 $0
Q2 2022

May 14, 2024

SELL
$1.15 - $3.34 $193,272 - $561,330
-168,063 Reduced 34.04%
325,639 $521,000
Q2 2022

Aug 15, 2022

SELL
$1.15 - $3.34 $936,982 - $2.72 Million
-814,767 Reduced 71.45%
325,639 $521,000
Q1 2022

May 16, 2022

BUY
$2.96 - $7.76 $519,565 - $1.36 Million
175,529 Added 18.19%
1,140,406 $3.51 Million
Q4 2021

Feb 14, 2022

BUY
$7.4 - $11.66 $2.26 Million - $3.56 Million
305,410 Added 46.31%
964,877 $7.14 Million
Q3 2021

Nov 10, 2021

BUY
$9.18 - $14.15 $6.05 Million - $9.33 Million
659,467 New
659,467 $7.61 Million

Others Institutions Holding DTIL

About PRECISION BIOSCIENCES INC


  • Ticker DTIL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 110,818,000
  • Market Cap $578M
  • Description
  • Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...
More about DTIL
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.